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Introduction
Hepatocellular carcinoma (HCC) is one of the commonest 
cancers in Asia, where hepatitis B viral (HBV) infection 
is endemic. Majority of these patients suffer from chronic 
HBV, which is defined as the presence of hepatitis B surface 
antigen (HBsAg) for more than 6 months. The loss of 
HBsAg with the development of anti-HBsAg indicates a 
resolution of the viral infection. Up to approximately 90% 
of the patients suffered from acute HBV infection would 
be able to clear the virus (1). For those patients that did not 
develop anti-HBsAg, they will progress to chronic hepatitis 
B, which is associated with a significant risk of developing 
liver cirrhosis and HCC (1).
Less than 1% of patients, who have been in the inactive 
phase of chronic HBV for many years, may lose the 
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presence of HBsAg and develop anti-HBsAg (2,3). With 
long-term follow-up of patients with HBsAg seroconversion 
(SC), there is evidence suggesting that the incidence of 
HCC in these patients is significantly lower than the non-
seroconverter (4). However, there is currently no data 
available in literature regarding whether there is any clinical 
and survival benefits for patients, who already had developed 
HCC, but with HBsAg SC after the initial HCC treatment.
The aim of this study is to investigate any difference 
in histological and hepatic function of patients with HCC 
secondary to hepatitis B, and also those who also developed 
HBsAg SC thereafter. Our second aim is to compare the 
overall survival (OS) of HCC between these two groups of 
patients.
Methods
Patients with chronic hepatitis B SC were identified 
retrospectively from a prospectively maintained database 
between 1989 and 2010. A single research assistant recorded 
all their clinical data prospectively into a computerized 
database. Patients were excluded from the study if they had 
co-existing hepatitis C or human immunodeficiency virus 
infection. Using a ratio of 1:8 [SC vs. non-seroconversion 
(NSC)], the HCC patients with the HBsAg SC group 
were case-matched against the NSC group according to 
their stage (AJCC/UICC 5th edition staging system) of the 
disease and their initial first treatment modality—resection, 
ablative therapy and palliation. 
Laboratory, diagnostic and histological evaluation
All patients had laboratory confirmation of their hepatitis 
B status at the point of diagnosis, and had had their HBsAg 
status re-checked after their first treatment and subsequent 
routine follow-up. HBsAg SC is defined as the persistent 
absence of serum HBsAg antigenemia for at least 12 months 
and until follow-up (3).
Hepatic function prior to the first treatment was assessed 
by Child-Pugh scoring (5), routine liver function test, 
serum platelet count and international normalised ratio. 
Preoperative alpha-feto-protein (AFP) level was performed 
prior intervention. Indocyanine green (ICG) clearance test 
was routinely performed for patient prior liver resection. 
Patient with ICG ≤14% at 15 minutes was considered safe 
for major hepatectomy in our practice (6).
Preoperative status of cirrhosis was determined on the 
basis of the findings of background liver biopsy and/or 
imaging findings complemented with clinical features of 
portal hypertension or encephalopathy (7,8).
Diagnosis of HCC was made by contrasted computer 
tomography (CT) or magnetic resonance imaging, without 
liver biopsy (7). Main portal vein invasion or distant 
metastasis was considered contraindication for surgical 
intervention. Imaging of all HCC patients were evaluated 
for resectability in a multi-disciplinary meeting. 
For those patients with liver resections and/or combined 
open ablative therapy, histopathological parameters 
including macro- and micro-vascular invasions, resection 
margin, tumour differentiation and the background liver 
status were evaluated. 
Postoperative follow-up
For patients with resection or ablative treatment modalities, 
they were follow-up within 1 month from discharge, and 
3 monthly thereafter. Surveillance contrast CT scan was 
performed between 4 to 6 weeks after the initial treatment/
operation, and was then performed 2–4 months thereafter. 
AFP was routinely performed during follow-up. Recurrence 
was confirmed by either imaging from CT, dual tracer 
(11C-acetate/18F-FDG) PET/CT (9), or histopathological 
diagnosis. 
Statistical analysis
The primary endpoint is to investigate for any difference in 
histological and hepatic functional parameters between SC 
and NSC groups; and the secondary endpoint is to compare 
OS among these two groups of patients in different 
treatment modalities. OS was defined as survival from the 
first diagnosis of HCC till death.
Categorical data were presented as frequencies and 
proportions (%), and were analysed using Pearson’s chi-squared 
test or Fisher’s exact test. Medians (range) were used to 
describe continuous data, and Mann-Whitney test was 
applied for the comparison of the two groups of patients. 
The Kaplan-Meier method was used to assess the OS for all 
treatment groups, and the log-rank test was used to compare 
the survival difference. 
Results
There were approximately 5,000 patients, who were 
diagnosed with HCC and were seen in our hospital, 
between 1989 and 2013. Thirty-nine patients infected 
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with chronic hepatitis B and subsequent HBsAg SC were 
identified and included into this study. Seventeen, 6 and 
16 patients of these patients had resections, open ablative 
procedures and palliation respectively. Three hundred and 
twelve patients were matched for the NSC group. One 
hundred and thirty-six, 48, and 128 patients had resections, 
open ablative procedures and palliation respectively in the 
corresponding NSC group. 
The median age for HCC diagnosis in the SC group 
was older (60 vs. 57 years, P<0.03). Patients in the SC 
group were associated with better liver function in 
terms of bilirubin (11 vs. 14 years, P<0.03), aspartate 
aminotransferase (31.0 vs. 49.5 years, P=0.001), and alanine 
aminotransferase (31.0 vs. 44.5 years, P<0.001). Majority 
of them had solitary liver nodule as compared to multifocal 
liver nodules in the NSC group (P=0.039). There was no 
statistical difference in Child-Pugh score between these two 
groups of patients (P=0.436) (Table 1).
For those patients with hepatectomies, there were no 
differences in macro- and microvascular invasion, tumour 
differentiations, and positive margins between SC and NSC 
groups. However, more NSC patients suffered from an 
underlying liver cirrhosis (P<0.001) and were associated with 
tumour infiltration to adjacent organs (P=0.006) (Table 2).
There was a trend towards a better OS for the SC group 
in combined treatment modalities, resection alone, ablative 
therapies and palliation. However, there was no statistical 
difference when OS was compared between SC and NSC 
in any of these treatment modalities in log-rank analyses. 
For recurrent pattern, majority of the SC (>70%) did not 
develop any recurrent disease, as opposed to over 60% of 
patients in the NSC group during their follow-up period. In 
spite of this, statistical difference was not achieved between 
these two groups (P=0.067).
One-, 3- and 5-year OS for SC vs. NSC were 65.6% vs. 
63.7%, 62.1% vs. 44.5%, and 55.9% vs. 38.7% respectively. 
After resection, 1-, 3- and 5- year OS were 81.4% vs. 
78.7%, 73.3% vs. 61.9%, and 73.3% vs. 52.6%. Similar 
trends suggesting better OS in SC group were also observed 
in open ablation therapy and in the palliation, with a 
5-year survival of 83.3% vs. 56.6% and 26.4% vs. 16.8% 
respectively (Figures 1-4).
Discussion
This is the first and largest study comparing both clinical 
and survival outcomes of HCC patients with/without 
HBsAg SC. In this series, we have identified that HCC 
patient with SC is associated with better underlying liver 
function prior treatment, mainly solitary tumour nodule, 
and less underlying liver cirrhosis at surgical intervention. 
Although we did not demonstrate a significant survival 
benefits, there was a trend suggesting a better survival 
outcomes for HCC in patients with HBsAg SC. 
In our cohort, we identified better preserved liver 
function in HCC patients of the SC group as compared to 
non-seroconverter. This finding is in consistent with other 
reports, which suggested significant reduction of alanine 
aminotransferase among patients with SC (3,10-12). This 
result can be explained by the fact that Hepatitis B virus 
is inactive among patients of the SC group, and therefore 
had less liver parenchymal damage. The other parameter 
that was different between our studied groups was age. In 
keeping with the findings in other study, older age group 
had been shown to be associated with an increased HBsAg 
SC (4). This makes sense because it is more likely that the 
older age group was at the inactive stage of the disease for a 
longer period than the younger group. 
We have also identified an increased proportion of 
HCC patients without HBsAg seroclearance suffered from 
underlying liver cirrhosis or chronic inflammation. By 
sustained suppression of HBV DNA, achieving HBeAg 
and/or HBsAg SC, other studies have shown a reduction in 
fibrosis, as well as regression in cirrhosis (10,13,14). Along 
with this improved liver histology, it is logical to explain the 
improved liver function described above.
Comparing the histological characteristic for the 
resection groups of SC and NSC, it is interesting to note 
that the liver tumour in NSC group was associated with 
more adjacent organ involvement and an increased presence 
of multifocal tumour nodules in the resected specimen. 
The multifocal nature of HCC in the NSC group could be 
explained by the fact that majority of these patients suffered 
from some degree of liver fibrosis or cirrhosis, which is an 
intrinsic factor for the increased likelihood in developing 
multifocal tumour nodules.
Looking at the trends of the OS in resections, ablative 
therapy and palliation, they appeared to illustrate a 
survival difference. However, despite all these favourable 
biochemical and histological tumour characteristics after 
HBsAg SC, these had not truly been translated into survival 
benefits statistically. One of the main reasons for not 
achieving a statistical difference is likely due to the small 
number of SC patients in our cohort. In one of the largest 
studies over a 21-year period with a median follow-up of 
62 months, only 2 out of 189 patients (1.1%), who had 
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Table 1 Patient demographic and laboratory data
Variables Seroconversion (n=39) Non-seroconversion (n=312) P value
Follow-up duration (month) 15.4 (0.2–91.6) 25.0 (0–276.6) 0.154
Age [median (range)] 60 (36.0–84.0) 57 (26.0–84.0) 0.027
Sex (male: female) 36:3 256:56 0.106
Serum bilirubin (mg/dL) 11 (5.0–27.0) 14 (3.0–109.0) 0.027
Albumin (g/L) 42 (26.0–48.0) 39 (24.0–50.0) 0.003
Haemoglobin (g/dL) 13.8 (7.9–18.5) 13.6 (7.6–18.2) 0.421
INR 1 (0.9–1.2) 1.1 (0.8–1.6) 0.019
Platelet count (×109/µL) 180 (78.0–713.0) 151 (22.0–621.0) 0.051
AFP (ng/mL) 49 (2.0–285,244.0) 135.5 (1.0–1,335,900.0) 0.064
AST (IU/L) 31 (18.0–420.0) 49.5 (18.0–444.0) 0.001
ALT (IU/L) 31 (11.0–371.0) 44.5 (13.0–325.0) 0.0003
Child-Pugh grade 0.436
A 30 (81.1%) 245 (79.0%)
B 7 (18.9%) 52 (16.8%)
C 0 (0%) 13 (4.2%)
Size of tumour (cm) [median (range)] 4.6 (1.1–20.0) 5 (0.5–26.0) 0.615
No. of tumour nodules [solitary (%)] 30 (76.9) 185 (59.9) 0.039
Treatment –
Resection 17 (43.6%) 136 (43.6%)
Ablative Tx 6 (15.4%) 48 (15.4%)
Palliative/no Tx 16 (41.0%) 128 (41.0%)
Pattern of recurrence 0.066
No recurrence 12 (70.6%) 50 (36.8%)
Intrahepatic recurrence 2 (11.8%) 39 (28.7%)
Extrahepatic recurrence 1 (5.9%) 15 (11.0%)
Both recurrence 2 (11.8%) 32 (23.5%)
UICC 5th edition –
Stage I 5 (12.8%) 40 (12.8%)
Stage II 11 (28.2%) 88 (28.2%)
Stage IIIA 6 (15.4%) 48 (15.4%)
Stage IIIB 1 (2.6%) 8 (2.6%)
Stage IVA 12 (30.8%) 96 (30.8%)
Stage IVB 4 (10.3%) 32 (10.3%)
AFP, alpha-feto-protein.
HBsAg SC, developed HCC (10). A similar incidence of 
HCC development in HBsAg seroconverters was also 
reported by Simonetti et al. (4). These studies highlighted 
the rarities of developing HCC in this cohort of patient, 
not alone the documentation of their long-term survival 
outcomes. Having identified a better absolute 5-year 
survival outcome in patients with HBsAg SC, we might be 
able to illustrate real survival benefits of SC with increasing 
the total number of patients over a longer period of time. 
One of the limitations in this series is its retrospective 
study design. To maximise the validity of the data, all data 
was prospectively collected and recorded by a single data 
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Table 2 Tumour characteristic for resection group in HCC patients with/without seroconversion
Tumour characteristic for resection group Seroconversion (n=17, %) Non-seroconversion (n=136, %) P value
Absence of invasion into major vein 14 (82.4) 114 (83.8) 1.000
Tumour differentiation 0.334
Well 2 (11.8) 29 (21.3)
Moderate 8 (47.1) 75 (55.1)
Poor 7 (41.2) 30 (22.1)
Undifferentiated 0 (0) 2 (1.5)
Presence of microvascular invasion 12 (70.6) 72 (52.9) 0.168
Positive resection margin 1 (5.9) 9 (6.6) 1.000
ICG-R15 (% of total) 11.7 (5.3–45.7) 13.5 (2.0–78.0) 0.466
Pathological liver status <0.001
Normal 9 (52.9) 6 (4.4)
Chronic hepatitis 2 (11.8) 48 (35.3)
Cirrhosis 6 (35.3) 82 (60.3)
Absence of invasion of adjacent organs other than gallbladder 13 (76.5) 129 (94.9) 0.006
Figure 1 Overall survivals for all treatment groups for HCC patients 
with/without seroconversion.
Overall survival rate Seroconversion (n=39) Non-seroconversion (n=312) P value
Overall survival (months)  
[median (range)]
>91.55 (0.20–91.55) 28 (0–276.57) 0.113
1-year 65.6% 63.7%
3-year 62.1% 44.5%
5-year 55.9% 38.7%
No. of patients remaining
Case 39 13 10 4 – – – – – – – – –
Control 312 158 110 82 57 41 26 16 8 4 1 – –
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Overall survival rate (resection) Seroconversion (n=17) Non-seroconversion (n=136) P value
Overall survival (months)  
[median (range)]
>88.1 (2.2–88.1) 63.95 (0.4–236.0) 0.426
1-year 81.4% 78.7%
3-year 73.3% 61.9%
5-year 73.3% 52.6%
No. of patients remaining
Case 17 5 4 2 – – – – – – –
Control 136 92 68 50 42 32 22 12 6 2 –
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Figure 2 Overall survivals for hepatectomies in HCC patients 
with/without seroconversion.
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Overall survival (months) 
[median (range)]
>68.1 (6.2–68.1) 78.3 (2.4–139.9) 0.349
1-year 83.3% 87.2%
3-year 83.3% 61.1%
5-year 83.3% 56.6%
No. of patients remaining
Case 6 4 3 – – –
Control 48 34 26 22 10 5
Figure 4 Overall survivals for palliation in HCC patients with/
without seroconversion.
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Seroconversion  
(n=16)
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(n=128)
P value
Overall survival (months)  
[median (range)]
9.3 (0.2–91.6) 7.4 (0–276.6) 0.185
1-year 39.6% 38.3%
3-year 39.6% 19.3%
5-year 26.4% 15.8%
No. of patients remaining
Case 16 4 3 2 – – – – – – – – –
Control 128 32 16 10 5 5 4 4 2 2 1 1 –
Figure 3 Overall survivals for ablative therapies in HCC patients 
with/without seroconversion.
manager. Other major drawbacks are the incompleteness of 
this set of data in obtaining all viral antigens status including 
HBsAg positivity; the viral loads i.e., the amount of HBV 
DNA, and the length of anti-viral treatment before and 
after the HBsAg SC. This will provide a more meaningful 
comparison of HCC developed in our two studied groups. 
In conclusion, this cohort is the first and largest study 
confirmed that HCC patients with HBsAg SC are associated 
with a better preserved underlying liver parenchyma and 
hepatic function, and might contribute to an improved 
long-term survival outcome. 
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